Review
Gastroenterology & Hepatology
Dickson Kofi Wiredu Ocansey, Sanhua Hang, Xinyi Yuan, Hua Qian, Mengjiao Zhou, Chinasa Valerie Olovo, Xu Zhang, Fei Mao
Summary: The gut microbiome plays a crucial role in integrating environmental inputs, genetics, and immune signals to affect the host's metabolism and immune response. Changes in gut bacteria have been shown to be linked to gastrointestinal conditions such as inflammatory bowel disease (IBD), suggesting the potential for improving IBD diagnosis, prognosis, and treatment through manipulating the gut microbiome. Advancements in sequencing techniques have allowed for a better understanding of the complexity of the gut microbial ecosystem, and current data shows promising results in predicting IBD compared to traditional biomarkers. This study reviews the differential potential of gut bacteria within IBD cohorts and between IBD and other gastrointestinal diseases.
Article
Microbiology
Julia Eckenberger, James C. Butler, Charles N. Bernstein, Fergus Shanahan, Marcus J. Claesson
Summary: The interaction between non-antibiotic drugs and the gut microbiome, as well as the effects of treatment on the composition of the gut microbiota in inflammatory bowel disease (IBD) patients, were investigated. The study found that treatments accounted for a relatively small proportion of the geographic contribution to microbiome variance between Irish and Canadian participants, but additive effects from multiple medications contributed significantly to microbiome differences between UC and CD.
Article
Cell Biology
Jun-Ichi Nagao, Sari Kishikawa, Honami Tanaka, Kenji Toyonaga, Yuka Narita, Kanae Negoro-Yasumatsu, Sonoko Tasaki, Ken-Ichi Arita-Morioka, Jiro Nakayama, Yoshihiko Tanaka
Summary: This study demonstrates that gut translocation of the oral pathobiont Porphyromonas gingivalis exacerbates periodontitis and enhances Th17 cell differentiation. The Th17 cells responsive to the oral pathobiont are differentiated in Peyer's patches and translocated to peripheral immune tissues, and they can migrate to and accumulate in the mouth upon oral infection. The development of periodontitis is regulated by the intestinal microbiome, and altering the microbiome composition affects the development of periodontitis.
Review
Biochemistry & Molecular Biology
Yuri Haneishi, Yuma Furuya, Mayu Hasegawa, Antonio Picarelli, Mauro Rossi, Junki Miyamoto
Summary: Inflammatory bowel disease (IBD) is a rapidly increasing inflammatory disease of the gastrointestinal tract worldwide. Recent research suggests that factors such as genetics, environment, microbiota, and immune responses are involved in its development, but the underlying causes are unclear. Dysbiosis of gut microbiota, particularly a decrease in specific genera, has been identified as a possible trigger for IBD. Improving gut microbiota and identifying specific bacterial species are crucial for understanding and treating IBD and autoimmune diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Microbiology
Anthea Pisani, Philipp Rausch, Corinna Bang, Sarah Ellul, Trevor Tabone, Claire Marantidis Cordina, Graziella Zahra, Andre Franke, Pierre Ellul
Summary: Dysbiosis in inflammatory bowel disease (IBD) has been identified as a potential cause or contributing factor to the development of the disease. Even after acute inflammation has subsided, significant differences and changes in community dynamics are observed in IBD patients. The gut microbiota is thought to play a crucial role in the development of IBD, and this study suggests that it is also a driver of chronicity in the disease, even in a state of remission.
MICROBIOLOGY SPECTRUM
(2022)
Review
Immunology
Peng Qiu, Takatsugu Ishimoto, Lingfeng Fu, Jun Zhang, Zhenyong Zhang, Yang Liu
Summary: Crohn's disease and ulcerative colitis are two main forms of inflammatory bowel disease (IBD), and intestinal microorganisms play a key role in the development and maintenance of these diseases. However, the specific causes of IBD are still unclear, and it is unknown whether a single transmissible agent is involved. Changes in the bacterial communities in the gut may be due to inflammatory reactions and tissue destruction, rather than causing the disease itself. Antibiotic therapy has generally been ineffective in treating IBD, but recent studies suggest that manipulating the gut microbiota and interacting with the gut immune system through probiotics, prebiotics, and synbiotics may hold potential in controlling these diseases.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Nutrition & Dietetics
Namrata Iyer, Sinead C. Corr
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease with a multifactorial etiology involving genetic, microbial, and environmental factors. The intestinal epithelium plays a central role in disease pathogenesis, while microbial metabolites are key regulators of gut homeostasis and the pathogenesis of IBD.
Review
Immunology
Michael Eberhardson, Yaakov A. Levine, Laura Tarnawski, Peder S. Olofsson
Summary: Inflammatory bowel diseases are characterized by chronic intestinal inflammation that typically begins in adolescents and young adults. Current treatment options are limited, and the role of the central nervous system in gut inflammation has become a focus for potential new therapies.
INTERNATIONAL IMMUNOLOGY
(2021)
Review
Gastroenterology & Hepatology
Manasvini Markandey, Aditya Bajaj, Nicholas Edward Ilott, Saurabh Kedia, Simon Travis, Fiona Powrie, Vineet Ahuja
Summary: Intestinal epithelium, composed of a dynamic and diverse cellular system interacting with gut commensals and external cues, relies on intestinal stem cells for replenishment and differentiation to maintain a functional epithelial cell population. The intricate micro-environment shaping the intestinal stem cell niche undergoes dynamic changes during homeostasis and chronic intestinal inflammation. Inflammatory bowel disease is characterized by compositional and functional alterations in gut microbiota, which modulate the intestinal stem cell niche and affect epithelial and immune cell types through direct or indirect mechanisms.
Review
Pharmacology & Pharmacy
Dulce C. Macias-Ceja, Maria D. Barrachina, Dolores Ortiz-Masia
Summary: Chronic inflammation is associated with excessive deposition of extracellular matrix and leads to fibrosis. Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD), and deregulated autophagy is linked to fibrosis progression. Understanding the role of autophagy in fibrosis may provide new targets for antifibrotic therapy. This review focuses on the relevance of autophagy in fibrosis, with a special emphasis on IBD-related fibrosis.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Infectious Diseases
Sara Federici, Denise Kviatcovsky, Rafael Valdes-Mas, Eran Elinav
Summary: Inflammatory bowel disease (IBD) is a group of auto-inflammatory disorders affecting the gastrointestinal tract and other organs. The gut microbiome and specifically bacteriophages, which can infect bacteria, play a role in IBD pathology. Phage therapy shows potential in eradicating pathobionts associated with IBD, but further research is needed.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Microbiology
Ram Hari Dahal, Shukho Kim, Yu Kyung Kim, Eun Soo Kim, Jungmin Kim
Summary: The gut microbiome consists of bacterial, archaeal, fungal, and viral communities. Various factors such as diet, age, stress, host genetics, and diseases can affect the diversity and abundance of bacterial species in the gut (dysbiosis). This study aimed to investigate the gut microbial composition in healthy controls (HCs) with Crohn's disease (CD), ulcerative colitis (UC), and ischemic colitis (IC) and identify biomarkers for distinguishing these conditions. The researchers used culture-independent and culture-based methods to analyze the gut microbial profile and validated biomarkers using quantitative Real-Time PCR (qPCR). They found that CD, UC, and IC conditions were associated with reduced bacterial diversity and species richness compared to HCs. Specific changes in microbial abundance were observed, including a decrease in Faecalibacterium prausnitzii and Prevotella sp. and an increase in potentially pathogenic bacteria such as Enterococcus faecium, Enterococcus faecalis, and Escherichia coli. Different bacteria were found to be abundant in CD, UC, and IC patients, suggesting potential biomarkers for each condition. Faecalibacterium prausnitzii reduction and increased abundance of specific bacteria could serve as biomarkers for CD, UC, and IC, respectively, aiding in diagnosis.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Immunology
Yongshun Ma, Yao Zhang, Jianghou Xiang, Shixin Xiang, Yueshui Zhao, Mintao Xiao, Fukuan Du, Huijiao Ji, Parham Jabbarzadeh Kaboli, Xu Wu, Mingxing Li, Qinglian Wen, Jing Shen, Zhongmin Yang, Jing Li, Zhangang Xiao
Summary: The study investigated changes in intestinal bacteria in healthy individuals, patients with IBD, and patients with CRC, revealing significant differences in the taxonomic and functional composition of intestinal bacteria in IBD and CRC patients compared to healthy individuals.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Nutrition & Dietetics
Hala Elzayat, Ghaidaa Mesto, Farah Al-Marzooq
Summary: Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic inflammation of the gastrointestinal tract (GIT). Recent research has shown the significant role of the oral and gut microbiome in the development and progression of IBD and their impact on overall gut health. The interconnected oral and gut microbiome, as complex microbial communities, are implicated in IBD pathogenesis, and understanding their relationship can provide insights into disease management and prevention strategies.
Review
Gastroenterology & Hepatology
Ana Elisa Valencise Quaglio, Thais Gagno Grillo, Ellen Cristina Souza De Oliveira, Luiz Claudio Di Stasi, Ligia Yukie Sassaki
Summary: Dysbiosis in the gut microbiota is closely associated with various gastrointestinal disorders such as IBS, IBD, and CRC, potentially leading to mucosal barrier disruption, chronic inflammation, and cancer progression. Specific harmful bacteria, like E. coli and ETBF, are linked to an increased risk of developing CRC.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Raquel Guerrero-Alba, Eduardo E. Valdez-Morales, Nestor N. Jimenez-Vargas, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Takanobu Okamoto, Yasmin Nasser, Nigel W. Bunnett, Alan E. Lomax, Stephen J. Vanner
Article
Gastroenterology & Hepatology
Lincon A. Stamp, Rachel M. Gwynne, Jaime P. P. Foong, Alan E. Lomax, Marlene M. Hao, David I. Kaplan, Christopher A. Reid, Steven Petrou, Andrew M. Allen, Joel C. Bornstein, Heather M. Young
Article
Gastroenterology & Hepatology
Sung Jin Park, Yang Yu, Brittany Wagner, William C. Valinsky, Alan E. Lomax, Michael J. Beyak
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2018)
Article
Pharmacology & Pharmacy
Raquel Guerrero-Alba, Eduardo Emmanuel Valdez-Morales, Nestor Nivardo Jimenez-Vargas, Romke Bron, Daniel Poole, David Reed, Joel Castro, Melissa Campaniello, Patrick A. Hughes, Stuart M. Brierley, Nigel Bunnett, Alan E. Lomax, Stephen Vanner
BRITISH JOURNAL OF PHARMACOLOGY
(2018)
Review
Physiology
Colin Reardon, Kaitlin Murray, Alan E. Lomax
PHYSIOLOGICAL REVIEWS
(2018)
Review
Gastroenterology & Hepatology
Alan E. Lomax, Sabindra Pradhananga, Jessica L. Sessenwein, Deryla O'Malley
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2019)
Article
Gastroenterology & Hepatology
Yang Yu, Egina C. Villalobos-Hernandez, Sabindra Pradhananga, Corey C. Baker, Christopher Keating, David Grundy, Alan E. Lomax, David E. Reed
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2019)
Article
Gastroenterology & Hepatology
Caroline J. Tuck, Alberto Caminero, Nestor N. Jimenez Vargas, Carmen L. Soltys, Josue O. Jaramillo Polanco, Cintya D. Lopez Lopez, Marco Constante, Sandra R. Lourenssen, Elena F. Verdu, Jane G. Muir, Alan E. Lomax, David E. Reed, Stephen J. Vanner
NEUROGASTROENTEROLOGY AND MOTILITY
(2019)
Article
Neurosciences
Sabindra Pradhananga, Ayssar A. Tashtush, Emma Allen-Vercoe, Elaine O. Petrof, Alan E. Lomax
JOURNAL OF PHYSIOLOGY-LONDON
(2020)
Article
Multidisciplinary Sciences
Nestor N. Jimenez-Vargas, Jing Gong, Matthew J. Wisdom, Dane D. Jensen, Rocco Latorre, Alan Hegron, Shavonne Teng, Jesse J. DiCello, Pradeep Rajasekhar, Nicholas A. Veldhuis, Simona E. Carbone, Yang Yu, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Meritxell Canals, David E. Reed, Alan E. Lomax, Brian L. Schmidt, Kam W. Leong, Stephen J. Vanner, Michelle L. Halls, Nigel W. Bunnett, Daniel P. Poole
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Gastroenterology & Hepatology
Nestor Nivardo Jimenez-Vargas, Yang Yu, Dane D. Jensen, Diana Daeun Bok, Matthew Wisdom, Rocco Latorre, Cintya Lopez, Josue O. Jaramillo-Polanco, Claudius Degro, Mabel Guzman-Rodriguez, Quentin Tsang, Zachary Snow, Brian L. Schmidt, David E. Reed, Alan Edward Lomax, Kara Gross Margolis, Christoph Stein, Nigel W. Bunnett, Stephen J. Vanner
Summary: The fentanyl analogue NFEPP demonstrated effectiveness in inhibiting pain response in mice with colitis in an acidic environment, without causing respiratory depression, constipation, or hyperactivity. In contrast, fentanyl inhibited pain responses in both groups of mice and had side effects such as respiratory depression and hyperactivity.
Article
Gastroenterology & Hepatology
Caroline J. Tuck, Amal Abu Omar, Giada De Palma, Samira Osman, Nestor N. Jimenez-Vargas, Yang Yu, Sean M. P. Bennet, Cintya Lopez-Lopez, Josue O. Jaramillo-Polanco, Corey C. Baker, Aidan S. W. Bennett, Mabel Guzman-Rodriguez, Quentin Tsang, Taylor Alward, Sebastien Rolland, Celine Morissette, Elena F. Verdu, Premysl Bercik, Stephen J. Vanner, Alan E. Lomax, David E. Reed
Summary: Objective dietary therapies for IBS have shown that reducing the consumption of fermentable carbohydrates can relieve abdominal pain. This study suggests that changes in luminal neuroactive metabolites may contribute to the reduction in pain symptoms.
Article
Gastroenterology & Hepatology
Alan E. Lomax, Sabindra Pradhananga, Paul P. Bertrand
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2017)